CYTOMX THERAPEUTICS INC (CTMX)
US23284F1057 - Common Stock
CTMX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 570 industry peers in the Biotechnology industry. CTMX may be in some trouble as it scores bad on both profitability and health. CTMX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CTMX was profitable.
CTMX had a negative operating cash flow in the past year.
CTMX had negative earnings in each of the past 5 years.
CTMX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of CTMX (9.95%) is better than 96.65% of its industry peers.
Looking at the Return On Invested Capital, with a value of 26.84%, CTMX belongs to the top of the industry, outperforming 99.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.95% | ||
| ROE | N/A | ||
| ROIC | 26.84% |
ROA(3y)-24.16%
ROA(5y)-22.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of CTMX (10.92%) is better than 95.41% of its industry peers.
CTMX has a Operating Margin of 5.30%. This is amongst the best in the industry. CTMX outperforms 94.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.3% | ||
| PM (TTM) | 10.92% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CTMX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for CTMX has been increased compared to 1 year ago.
CTMX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CTMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -5.69, we must say that CTMX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CTMX (-5.69) is worse than 64.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.69 |
ROIC/WACC2.58
WACC10.42%
2.3 Liquidity
CTMX has a Current Ratio of 1.04. This is a normal value and indicates that CTMX is financially healthy and should not expect problems in meeting its short term obligations.
CTMX has a worse Current ratio (1.04) than 88.18% of its industry peers.
A Quick Ratio of 1.04 indicates that CTMX should not have too much problems paying its short term obligations.
CTMX's Quick ratio of 1.04 is on the low side compared to the rest of the industry. CTMX is outperformed by 86.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.04 | ||
| Quick Ratio | 1.04 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 136.96% over the past year.
CTMX shows a strong growth in Revenue. In the last year, the Revenue has grown by 67.59%.
Measured over the past years, CTMX shows a quite strong growth in Revenue. The Revenue has been growing by 11.21% on average per year.
EPS 1Y (TTM)136.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)67.59%
Revenue growth 3Y0.27%
Revenue growth 5Y11.21%
Sales Q2Q%26.71%
3.2 Future
Based on estimates for the next years, CTMX will show a very negative growth in Earnings Per Share. The EPS will decrease by -32.47% on average per year.
Based on estimates for the next years, CTMX will show a small growth in Revenue. The Revenue will grow by 1.62% on average per year.
EPS Next Y-163.52%
EPS Next 2Y-369%
EPS Next 3Y-238.87%
EPS Next 5Y-32.47%
Revenue Next Year27.18%
Revenue Next 2Y-8.21%
Revenue Next 3Y-29.38%
Revenue Next 5Y1.62%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 7.59, the valuation of CTMX can be described as very cheap.
98.77% of the companies in the same industry are more expensive than CTMX, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 29.59, CTMX is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for CTMX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.59 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -11.52 |
4.3 Compensation for Growth
A cheap valuation may be justified as CTMX's earnings are expected to decrease with -238.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-369%
EPS Next 3Y-238.87%
5. Dividend
5.1 Amount
No dividends for CTMX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CYTOMX THERAPEUTICS INC
NASDAQ:CTMX (12/4/2024, 8:00:00 PM)
After market: 1.29 0 (0%)1.29
+0.06 (+4.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap100.96M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.59 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.95% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 5.3% | ||
| PM (TTM) | 10.92% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.91
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.04 | ||
| Quick Ratio | 1.04 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)136.96%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-163.52%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)67.59%
Revenue growth 3Y0.27%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y